Background
Methods
Patients and tissue samples
Reagents
Immunohistochemical staining
Cell culture and transfection
Cell viability assay
Statistical analysis
Results
Baseline characteristics
Variables | Incidence (SD or %) | |
---|---|---|
Age mean (SD) | 57 (6.6) | |
No. gender (%) | Male | 53(91.4) |
Female | 5 (8.6) | |
No. clinical T stage (%) | T2 | 7 (12.1) |
T3 | 30 (51.7) | |
T4a | 18 (31.1) | |
T4b | 3 (5.2) | |
No. pathologic T stage (%) | TIS | 1 (1.7) |
T1 | 1 (1.7) | |
T2a | 7 (12.1) | |
T2b | 7 (12.1) | |
T3a | 22 (37.9) | |
T3b | 15 (25.9) | |
T4a | 5 (8.6) | |
No. pathologic N status (%) | N0 | 5 (8.6) |
N1 | 14 (24.1) | |
N2 | 37 (63.8) | |
N3 | 2 (3.4) | |
No. lymphovascular invasion (%) | Yes | 45 (77) |
No | 13 (23) | |
No. strong EGFR expression (%) | Yes | 10 (17.2) |
No | 48 (82.8) |
EGFR expression is negatively correlated with survival
Covariate | Univariate | Multivariate | ||
---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Age | 1.41 (1.02–2.45) | 0.029 | 1.34 (0.94–1.77) | 0.056 |
Sex (M vs F) | 1.88 (1.06–3.34) | 0.048 | 1.48 (0.26–1.80) | 0.479 |
EGFR expression (strong vs negative/weak/moderate) | 1.55 (1.30.-2.33) | 0.002 | 1.38 (1.201–2.744) | 0.004 |
Chemotherapy Regimen (MVAC vs GemCis) | 1.72 (0.84–3.75) | 0.159 | ||
pT stage (T2 or less vs greater than T2) | 2.88 (1.92–3.99) | 0.003 | 3.28 (1.54–4.62) | < 0.001 |
pN stage (N0 vs greater than N0) | 2.31 (1.88–2.93) | < 0.001 | 1.81 (1.23–2.74) | < 0.001 |